Natco Pharma update: Risdiplam launch awaits court clarity

Hyderabad-based Natco Pharma (BSE: 524816, NSE: NATCOPHARM) today provided an update on its planned launch of generic Risdiplam in India. While a single judge had denied Roche's injunction plea, Roche appealed. A final decision from the Appellate Bench is expected shortly. The company stated its intention to launch the drug only after and subject to successful clarity from the courts. Despite the legal uncertainty, Natco announced it would price Risdiplam at INR 15,900 MRP, consistent with its previous statements. Natco also intends to offer a patient access program to provide discounts to deserving patients. Natco Pharma is a R&D-oriented pharmaceutical company focused on oncology and specialty products.